reports
Nature Cell and Biostar Stem Cell Research Institute Begin World’s F...
SEOUL, South Korea--(BUSINESS WIRE)-- South Korea’s Biostar Stem Cell Research Institute (CEO: Jeong-Chan Ra), jointly operated by Nature Cell and Rbio, today announced that Trinity Clinic Fukuoka, a partner hospital in Japan, received approval for the application of regenerative medicine in Alzheimer’s disease and officially began stem cell treatment as of April 12. Earlier in March, Trinity Clinic Fukuoka received approval from the Kyushu Certified Special Committee for Regenerative Medicine for the safety and effect...
Safety of Intravenous Administration of Biostar’s Cultured Stem Cell...
SEOUL, South Korea--(BUSINESS WIRE)-- A clinical study on safety found that multiple intravenous administrations of cultured human autologous adipose-derived stem cells which were cultured by Biostar Stem Cell Research Institute do not affect the incidence of cancer in human subjects. Nature Cell(KOSDAQ: 007390), a high-tech Bio company and Biostar Stem Cell Research Institute (Chairman JeongChan Ra) announced on the 5th January that there was no association between incidence of cancer and the intravenous administration of au...
Nature Cell Started Commercial Clinical Trials Phase I and II ‘ASTRO...
SEOUL, South Korea--(BUSINESS WIRE)-- Biotechnology enterprise Nature Cell (KOSDAQ:007390) announced that it had started to recruit patients for its clinical trials of ‘ASTROSTEM,’ a stem cell drug for Alzheimer's disease treatment, in the U.S. The phase I and II clinical trials regarding Alzheimer's disease were approved by the U.S. FDA on November 24th, 2016. In February 2017, IRB approval was obtained regarding the clinical trial protocol and on March 8th, 2017, IRB final approval was obtained regarding Syrentis Cli...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.